Patient description: The patient is a 47-year-old Asian woman complaining of persistent feelings of sadness. She lost interest in activities she used to enjoy. She states that her mood is mostly depressed for the past 3 weeks. She also lost her appetite , which led to about 5kg weight loss. She complains of loss of energy and feelings of worthlessness nearly every day. She is not using any drugs and she does not smoke. She doesn't drink alcohol. She used to exercise every day for at least 30 min. But she doesn't have enough energy to do so for the past 3 weeks. She also has some digestive issues recently. She is married and has 4 children. She is menopausal. Her husband was recently diagnosed with colon cancer and he is starting his chemotherapy. There is nothing remarkable in her past medical history and her drug history is only positive for Vit D3 1000 units daily. Her family history is negative for any psychologic problems. Her HAM-D score is 20.

Clinical trial eligibility criteria: eligible ages (years): 17.0-65.0,  C3 Glomerulonephritis C3 Glomerulopathy Immune Complex Membranoproliferative Glomerulonephritis IC-MPGN Dense Deposit Disease Key 1. 17 to 65 years of age 2. Completion of the ACH471-201 clinical study OR diagnosed with biopsy-confirmed primary C3G or IC-MPGN at least 3 months prior to the first dose of study drug, prior to 55 years of and not secondary to another underlying condition 3. No more than 50% fibrosis and no more than 50% of glomeruli with cellular crescents on renal biopsy 4. Clinical evidence of ongoing disease based on at least one of the following findings attributable to C3G disease or IC-MPGN: significant proteinuria, defined as ≥1 g/day of protein in a 24-hour urine OR an abnormal eGFR, defined as ≤75 mL/min/1.73 m2 ( CKD-EPI equation for patients > 19 years old; "Bedside Schwartz" equation for patients <19 years old). 5. On a stable dose of anti-hypertensive medication, anti-proteinuric medications or mycophenolate mofetil (MMF) for at least 4 weeks prior to the first screening visit 6. Female participants must use highly effective birth control to prevent pregnancy during the clinical trial and for 30 days after the last dose of study medication 7. Male participants must use highly effective birth control with a female partner to prevent pregnancy during the clinical trial and for 90 days after the last dose of study medication 8. Must be up-to-date on routine vaccinations, or willing to be brought up-to-date, based on local guidelines 9. Must be willing, at all times for the duration of study participation, to have transportation and telephone access, and to be within one hour of an emergency medical center Key  Have a history of a major organ transplant (e.g., heart, lung, kidney, liver) or hematopoietic stem cell/marrow transplant 2. Have an estimated GFR <30 mL/min/1.73 m2 at the time of screening or at any time over the preceding four weeks 3. Is receiving renal replacement therapy 4. Have evidence of monoclonal gammopathy of unclear significance(MGUS), infections, malignancy, autoimmune diseases, or other conditions to which C3G or IC-MPGN may be secondary 5. Have a history of febrile illness, a body temperature >38°C, or other evidence of a clinically significant active infection, within 14 days prior to ACH-0144471 administration 6. Positive serology for human immunodeficiency virus, hepatitis B infection, or hepatitis C infection 7. Have a history of meningococcal infection, or a first-degree relative or household contact with a history of meningococcal infection 8. . Have received eculizumab at any dose or interval within the past 75 days prior to the first dose of ACH-0144471 9. Have received tacrolimus or cyclosporine within 2 weeks of the first dose of ACH-0144471 10. Have received blood or blood products, or undergone plasmapheresis or plasma exchange, within 30 days of screening NOTE: Additional inclusion/ will apply, per protocol